New Treatment Challenges for EGFR-Mutant Lung Cancer!
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- July 4, 2025
- Read time: 1 minute
[Treatment Challenges in EGFR-Mutant Non-Small Cell Lung Cancer] Detection of EGFR gene mutations and targeted therapy have greatly improved outcomes for non-small cell lung cancer patients. However, these patients are more prone to brain metastases — especially those unresponsive to EGFR tyrosine kinase inhibitors (EGFR-TKI) — becoming a major clinical challenge.
Key Data:
- Among EGFR-mutant patients, the incidence of brain metastases is significantly higher than other cancer types.
- Patients unresponsive to EGFR-TKI have a further 50% increased risk of brain metastasis.
- Effective treatment regimens are being continuously explored to improve patient quality of life.
More details: https://tinyurl.com/26x4trtw
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4